National Institute of Health and Medical Research (INSERM)
Ile-de-France (FR1) · France
ERC Starting Grant · 2022
Breaching the protective cancer stroma with radiotherapy-responsive liposomes
Liposomes have been the most successful type of nanomedicine for cancer patients, playing a leading role in improving the tolerability of chemotherapeutics. However, to advance the success of liposomal drug delivery and cancer treatment, new approaches to physically trigger drug release in cancer tissues and increase the permeability of the protective cancer stroma are needed. This project will investigate whether radiocatalytic nanomaterials can be integrated in liposomes for spatiotemporal-controlled drug release, the alleviation of cancer desmoplasia, and improved efficacy of co-encapsulated drugs. Liposomes will be composed of oxidation-susceptible phospholipids that encapsulate…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.
← All labs at National Institute of Health and Medical Research (INSERM)